Scientists have created double-blind studies so that neither the subjects of the experiment nor scientists know whether a patient is receiving an actual drug or a placebo, which is nothing more than a sugar pill. Essentially, if one knows that one is receiving an actual drug, such knowledge can affect the outcome of a study. A recent study on the effectiveness of the Selective Serotonin Reuptake Inhibitor (SSRI) Freloxamine on depression found that those subjects administered the drug were 15% more likely to have a decrease in symptoms than the control group, which was comprised of those who received a placebo. Since neither group knew which they were receiving, the placebo or the SSRI inhibitor, the observed drop in depression can only be attributed to Freloxamine.